Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Wiktoria Feret


Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor progesterone receptors and lack overexpression of human epidermal growth factor receptor. As no hormone therapy can be implemented, chemotherapy remains the main weapon. Nowadays, widely available chemo regimens for TNBC treatment can consist of anthracyclines, taxanes, antimetabolites, or platinums, but all of the aforementioned are highly toxic to the bone marrow, liver, kidneys,
and nervous system. Targeted treatment using nanotechnology seems to be a ray of hope in impeding this morbid disease.


triple negative breast cancer; nanotechnology; nanoparticles; oncology.

Full Text:



Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J 2021;27(1):8-16. doi: 10.1097/PPO.0000000000000500.

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23 Suppl 6:vi7-12. doi: 10.1093/ annonc/mds187.

Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, et al. Evaluation of racial/ ethnic differences in treatment and mortality among women with triple- -negative breast cancer. JAMA Oncol 2021;7(7):1016-23. doi: 10.1001/ jamaoncol.2021.1254.

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel) 2020;12(9):2392. doi: 10.3390/cancers12092392.

Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target 2016;24(3):179-91. doi: 10.3109/1061186X.2015.1051049.

Lungu II, Grumezescu AM, Volceanov A, Andronescu E. Nanobiomaterials used in cancer therapy: an up-to-date overview. Molecules 2019;24(19):3547. doi: 10.3390/molecules24193547.

Saraiva SM, Gutiérrez-Lovera C, Martínez-Val J, Lores S, Bouzo BL, Díez-Villares S, et al. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Sci Rep 2021;11(1):9873. doi: 10.1038/s41598-021-87968-4.

Lasa-Saracíbar B, Aznar MÁ, Lana H, Aizpún I, Gil AG, Blanco-Prieto MJ. Lipid nanoparticles protect from edelfosine toxicity in vivo. Int J Pharm 2014;474(1-2):1-5. doi: 10.1016/j.ijpharm.2014.07.053.

Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Adv Exp Med Biol 2019;1136:1-18. doi: 10.1007/978-3-030-12734-3_1.

Cheng FY, Chan CH, Wang BJ, Yeh YL, Wang YJ, Chiu HW. The oxygen- -generating calcium peroxide-modified magnetic nanoparticles attenuate hypoxia-induced chemoresistance in triple-negative breast cancer. Cancers (Basel) 2021;13(4):606. doi: 10.3390/cancers13040606.

Verry C, Porcel E, Chargari C, Rodriguez-Lafrasse C, Balosso J. Utilisation de nanoparticules comme agent radiosensibilisant en radiothérapie: où en est-on? Cancer Radiother 2019;23(8):917-21. doi: 10.1016/j. canrad.2019.07.134.

Her S, Jaffray DA, Allen C. Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements. Adv Drug Deliv Rev 2017;109:84-101. doi: 10.1016/j.addr.2015.12.012.

Janic B, Brown SL, Neff R, Liu F, Mao G, Chen Y, et al. Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer. Cancer Biol Ther 2021;22(2):124-35. doi: 10.1080/15384047.2020.1861923.

Simons M, Raposo G. Exosomes – vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009;21(4):575-81. doi:10.1016/j. ceb.2009.03.007.

Zhou X, Xie F, Wang L, Zhang L, Zhang S, Fang M, et al. The function and clinical application of extracellular vesicles in innate immune regulation. Cell Mol Immunol 2020;17(4):323-34. doi: 10.1038/s41423-020-0391-1.

Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci 2019;110(10):3173-82. doi: 10.1111/cas.14181.

DOI: https://doi.org/10.21164/pomjlifesci.792

Copyright (c) 2022 Wiktoria Feret

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/